CHESS ROBERT 4

What Happened

• Robert Chess, a director of Twist Bioscience (TWST), exercised stock options and sold shares on March 17, 2026. He exercised options to acquire 10,000 shares at $11.89 per share (cost $118,900) and sold 10,000 shares in the open market at $47.00 per share (proceeds $470,000). The filing also reports a conversion/disposition of 10,000 derivative shares with no cash proceeds.

Key Details

• Transaction dates and prices: March 17, 2026 — exercised 10,000 shares at $11.89 (acquired, $118,900); sold 10,000 shares at $47.00 (disposed, $470,000); reported conversion/disposition of 10,000 derivative shares at $0.
• Plan: Transactions were made pursuant to a Rule 10b5-1 trading plan adopted December 10, 2025 (footnote F1).
• Vesting/option info: The option is immediately exercisable; vesting began in 2018 and continued monthly thereafter per filing (footnote F3).
• Ownership: The filing identifies the Reporting Person and spouse as trustees/beneficiaries of the Chess 1997 Trust (footnote F2). The Form 4 excerpt provided does not state the number of shares beneficially owned after these transactions.
• Filing timeliness: Form filed March 19, 2026 reporting March 17 transactions — appears timely based on the filing date and reported transaction date.

Context

• This sequence (exercise of options followed by a sale) is commonly a cashless-style exercise where newly acquired shares are sold; the separate $0 derivative disposition line may reflect a net settlement, tax withholding, or share surrender associated with the option exercise (filings sometimes show these mechanics explicitly). Because the sale was made under a pre-established 10b5-1 plan, it likely followed predetermined instructions rather than ad hoc trading.